SCHEDULE: FMR LLC Discloses 10% Stake in Agomab Therapeutics SA

FMR LLC and Abigail P. Johnson have reported a 10.0% beneficial ownership stake in Agomab Therapeutics SA, totaling 4,873,680 common shares.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 4,873,680 shares of AGOMAB THERAPEUTICS SA common stock.
• This ownership represents 10.0% of the total outstanding common stock of AGOMAB THERAPEUTICS SA.
• The event requiring this filing occurred on February 27, 2026.
• FMR LLC, a Delaware-organized entity, holds sole voting and dispositive power over all 4,873,680 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over the 4,873,680 shares, but no sole voting power.
• Fidelity Management & Research Company LLC (an Investment Adviser) and Fidelity Management Trust Company (a Bank) are identified as relevant entities within FMR LLC that beneficially own shares.
• The Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC, representing 49% of its voting power, and form a controlling group with respect to FMR LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it signals strong institutional confidence in Agomab Therapeutics SA, with a major asset manager taking a significant ownership position.

Positives

• A significant institutional investor like FMR LLC taking a 10% stake can signal confidence in Agomab Therapeutics SA's long-term prospects.
• The disclosure of a substantial ownership by a reputable financial institution may attract further investor interest and potentially stabilize the stock.

Management Comments

• FMR LLC and Abigail P. Johnson, through their duly authorized signatory Stephanie J. Brown, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that the disclosure of a 10% stake by a major asset manager like FMR LLC in a biotechnology company such as Agomab Therapeutics SA is a significant event. Such institutional investment often indicates a belief in the company's underlying value, pipeline, or market potential, potentially influencing other institutional and retail investors.

Stakeholder Impact

• Shareholders may view this as a positive signal, potentially leading to increased investor confidence and demand for the stock.
• The company's management might perceive this as validation of their strategy and operations, potentially influencing future strategic decisions.

Key Dates

Recommendation

A 'hold' recommendation is appropriate because while the disclosure of a 10% institutional stake by FMR LLC is a positive indicator of confidence in Agomab Therapeutics SA, this filing does not provide new operational or financial performance data to warrant a stronger 'buy' recommendation. It primarily signals institutional interest, which can be a supportive factor for the stock.

Keywords

Agomab Therapeutics SA, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Schedule 13G